This presentation will review the evolving role of radiation therapy in the management of oligometastatic malignancies, with an emphasis on prostate, renal, and urothelial cancers. The talk will highlight the biological and clinical rationale for metastasis-directed therapy, summarize key prospective and retrospective evidence supporting the use of stereotactic body radiation therapy and other focused radiation approaches, and discuss how patient selection, disease burden, imaging advances, systemic therapy integration, and treatment timing influence outcomes. Special attention will be given to the distinction between oligorecurrent, oligoprogressive, and de novo oligometastatic disease, as well as the potential
goals of radiation therapy, including delaying systemic therapy, improving progression-free survival, consolidating response, and palliation. The presentation will also address practical considerations for multidisciplinary decision-making, toxicity mitigation, and future directions, including biomarker-driven selection and ongoing clinical trials aimed at refining
the use of radiation therapy in this increasingly important clinical setting.